BioSpace News Archive

Following a delay and an initial rejection, UCB’s IL-17A/IL-17F blocker bimekizumab was approved for moderate-to-severe plaque psoriasis, which will now be marketed with the brand name Bimzelx.

The deal with PTC Therapeutics increases Royalty Pharma’s stake to 13% of total royalties garnered by Evrysdi, the blockbuster drug for spinal muscular atrophy licensed and marketed by Roche.

Early stage ALK-positive non-small cell lung cancer patients treated with Roche’s Alecensa saw an “unprecedented” 76% drop in the risk of recurrence or death, the company announced Wednesday.

The trial, which is the first late-stage study of an in vivo CRISPR treatment in the U.S., will start by the end of 2023. Intellia’s NTLA-2001 is a treatment candidate for transthyretin amyloidosis cardiomyopathy.

The contracting COVID-19 market has led to lower third-quarter sales for the Swiss drugmaker, which made the decision to eliminate four clinical programs following underwhelming readouts.

Basilea Pharmaceutica Ltd announced that it has entered into an asset purchase agreement with privately owned Gravitas Therapeutics Inc. for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species.

Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world’s premier pharmaceutical industry exhibitions.

Mayo Clinic and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, unveiled a multi-year joint development collaboration to develop new clinical tests for diseases and improve patient care.

Gilead Sciences, Inc. announced new long-term real-world data from the BICSTaR study highlighting the safety and efficacy profile of Biktarvy® as a treatment regimen for a broad range of people with HIV, including those with a prior treatment history or comorbidities.

AlzeCure Pharma AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer’s disease and pain, announced that the Japenese Patent Office has granted a patent covering the company’s leading candidate drug ACD856, from the NeuroRestore platform, which is developed against Alzheimer’s disease and other disorders with cognitive impairment.